Published in final edited form as:

Metabolism. 2011 January ; 60(1): 92–98. doi:10.1016/j.metabol.2009.12.022.

Metabolic Response to Endotoxin *in vivo* in the conscious mouse: role of interleukin-6

Andrea Tweedell, Kimberly X. Mulligan, Josie E. Martel, Fu-Yu Chueh, Tammy Santomango, and Owen P. McGuinness

Department of Molecular Physiology and Biophysics, Vanderbilt Univ. School of Medicine, Nashville, TN 37232-0615 USA

Abstract

Inflammation and insulin resistance are characteristics of endotoxemia. While the role of interleukin-6 (IL-6) in insulin resistant states has been characterized, little is known of its role in the metabolic response to inflammation. To study the role of IL-6, conscious chronically catheterized mice were used. Five days prior to being studied, catheters were implanted in the carotid artery and jugular vein. After a 5 h fast, *E. coli* (250 µg/mouse) LPS was injected in IL6^{-/-} (KO; n=13), and IL-6^{+/+} (WT; n=10) littermates. The IL-6 response to LPS was simulated in an additional group of KO mice (KO+IL6; n=10). IL-6 increased in WT (15±0.7 ng/ml) 4h after LPS and was undetectable in KO. IL-6 replacement in the KO restored circulating IL-6 to levels observed in the WT group (14±0.3ng/ml). Tumor necrosis factor-α (TNF-α) increased more rapidly in WT than in both KO and KO+IL6. KO exhibited a more profound glucose excursion 30 min after LPS injection and no apparent hypoglycemia at 4h (95±5 vs. 70±8 mg/dl; KO vs. WT), despite having a blunted glucagon and epinephrine response. Glucose levels in KO+IL6, while decreased (93±4 mg/dl) at 4h, remained higher than WT. In summary, the absence of IL-6 protected against LPS induced hypoglycemia. Acute restoration of the IL-6 response to LPS did not potentiate hypoglycemia but partially restored the glucagon response. Thus, while IL-6 promotes glucose intolerance in insulin resistant states, IL-6 promotes hypoglycemia during acute inflammation.

Keywords

glucose; catecholamines

Introduction

The pathogenic effects of gram-negative bacteria are primarily brought about by exposure within the mammalian host to the bacterial endotoxic component called lipopolysaccharide (LPS). Exposure to LPS results in a subsequent chain of events that varies widely but can consist of infection, septic shock, and eventually death (31). Patients with septicemia experience an increase in the mobilization and utilization of glucose in conjunction with a

Address all reprints to: Owen P. McGuinness, Ph.D., 702 Light Hall, Dept. Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232-0615, Phone 615-343-4473, FAX 615-322-1462, owen.mcguinness@vanderbilt.edu.

The authors have no conflict of interest or financial disclosures

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

major influx of immunologic factors. One important feature of the hypermetabolic response *in vivo* is an increase in the synthesis and release of glucose from the liver early in response to an LPS challenge (20,21). This generally leads to a brief state of hyperglycemia coupled with elevated insulin levels followed by in some cases hypoglycemia. The severity of the hypoglycemia is dependent upon the dose of LPS used, the species, and strain (13,20). Hypoglycemia develops despite marked insulin resistance, increased gluconeogenic precursor supply (lactate and gluconeogenic amino acids) and increased levels of counterregulatory hormones (21).

LPS activates the release of many pro- and anti-inflammatory cytokines. TNF- α is typically the first cytokine to appear in the circulation after LPS challenge and is thought to play a major role in lethality following endotoxic shock (14). This is followed shortly by other pro-inflammatory and anti-inflammatory cytokines including IL-1 β , IL-6, IL10, IL-12, and IFN- γ (6).

Glucose uptake is increased in many tissues especially those rich in macrophages following an LPS challenge. Interestingly, in rats *in vivo*, LPS has been shown to increase whole body glucose disposal. The enhanced glucose uptake by the periphery is distributed to barrier tissues such as the skin and lung as well as the spleen (22–25). TNF stimulates the same effect, leading one to speculate that this cytokine may play a crucial role in alterations in glucose uptake, yet neutralization of TNF does not completely block the overall metabolic response to endotoxin challenge (3). Thus it is likely that cytokine release following endotoxin exposure may be one of the mechanisms by which LPS exerts its effects on glucose metabolism (25). While many studies have been done in a number of species, the impact of LPS on tissue glucose uptake in the mouse has not been characterized.

It has been suggested that IL-1 contributes to the hypoglycemia seen during endotoxemia and IL-6 plays a lesser role (7). However, IL-6 is a unique cytokine exhibiting both pro- and anti-inflammatory properties depending on the target cell type. Physiological stimuli for the synthesis of IL-6 include IL-1, TNF, and bacterial endotoxin with levels increasing up to 300 fold during endotoxic insult. The lack of marked effects of IL-6 deficiency on glucose concentration may in part be due to offsetting effects of IL-6 on glucose kinetics. IL-6 can both augment and impair insulin action *in vivo* (5,15,16,19,28,30).

The pro- and anti-inflammatory nature of IL-6 adds many layers of complexity to discerning its role in a pathogenic state such as sepsis. There is a profound lack of data correlating the interaction of increased levels of IL-6 during inflammation with alterations in carbohydrate flux. This study examined the impact of IL-6 on the metabolic response to LPS *in vivo* in the presence and absence of the IL-6 protein.

Methods

Animal Care and Husbandry

All procedures were performed on IL-6^{-/-} mice on a C57BL/6 background (B6.129S2-*Il6*^{tm1Kopf}/J; Jackson Laboratories, Bar Harbor, ME) that were backcrossed to C57BL/6J mice for 5 generations to obtain two genotypes: IL6^{-/-} and IL6^{+/+}. Genotyping of mice was performed as described on Jackson laboratory web site. At three weeks of age, mice were separated by gender and maintained in micro-isolator cages on a 12-h light/dark cycle with free access to food and water. All experiments were performed at ~4 months of age. All procedures performed were approved by the Vanderbilt University Animal Care and Use Committee.

Surgical Procedures

The surgical procedures utilized to implant chronic catheters have previously been described (2,27). Briefly, mice were anesthetized with an injection of pentobarbital (70mg/kg body weight). The left common carotid artery and right jugular vein were catheterized for sampling and infusions, respectively. The free ends of the catheters were tunneled under the skin to the back of the neck where the loose ends of the catheters were attached via stainless steel connectors to tubing made of Micro-Renathane (0.033 in OD), which were exteriorized and sealed with stainless steel plugs. Animals were individually housed after surgery and body weight was recorded daily. The lines were flushed daily with ~50µl of saline containing 200U/ml of heparin and 5 mg/ml of ampicillin.

In Vivo Metabolic Experiments

All metabolic experiments were performed following a ~5-day postoperative recovery period, depending on restoration to 10% of pre-surgery body weight. For metabolic studies, conscious, unrestrained mice were placed in ~1-L plastic container lined with bedding and fasted for 5-h. Approximately 2-h prior to the experiment the animals were connected to a Dual Channel Stainless Steel Swivel (Instech Laboratories, Plymouth Meeting, PA.) to allow simultaneous jugular vein infusion and sampling of arterial blood. A 5 µCi bolus of 3-[³H]-D-glucose was then given into the jugular vein followed by a constant infusion at a rate of 0.05 µCi/min. Mice were not handled and allowed to move freely to eliminate stress. Approximately 1-h prior to an experiment, red blood cells from a donor mouse on a C57Bl/6 background washed with 0.9% heparinized saline were infused at a rate of 2µl/min for the duration of the study to minimize falls in the hematocrit. Following a 2-h equilibrium period (t = 0), a baseline arterial blood sample was drawn for measurement of blood glucose, 3-[³H]-D-glucose, hematocrit, plasma insulin, plasma glucagon, catecholamines, and cytokines.

The response to an LPS challenge was examined in three groups of mice: IL6^{-/-} (KO, n=13), IL6^{+/+} (WT, n=10), and IL6^{-/-} with replacement of interleukin-6 to stimulate the natural IL-6 response observed in WT (KO+IL-6, n=10). At t = 5 min mice were given a 250 µg/mouse bolus of E. coli endotoxin (LPS) followed by 25 µL saline (or saline alone) was given into the jugular vein catheter. In KO+IL-6 mice, immediately following the bolus of endotoxin, a constant infusion of rmIL-6 (16µg/hr) (Research Diagnostics, Inc., Flanders, NJ) at a rate of 1µL/min was begun and the clock was reset. At t=30 min, the infusion of rmIL-6 was increased to 32 µg/hr (pump rate=2µL/min) for the remainder of the study. In all groups at t = 30min, arterial blood was sampled to determine blood glucose, 3-[³H]-D-glucose, hematocrit, plasma insulin, glucagon, epinephrine, norepinephrine, and cytokines. Arterial blood samples were taken at t = 60,120,180, 210 and 240 min, to determine blood glucose, 3-[³H]-D-glucose, and cytokine levels. At t = 240, a 13 µCi bolus of 2-deoxy [¹⁴C] glucose ([2-¹⁴C]DG) was administered into the jugular vein catheter. At t = 242, 245, 250, 255, and 265 min arterial blood was sampled to determine blood glucose and plasma 3-[³H]-D-glucose and [2-¹⁴C]DG. At t = 265 min, a final arterial blood sample was taken to assess all hormones and plasma [2-¹⁴C]DG. The mice were then anesthetized. The soleus, gastrocnemius, SVL, omental adipose tissue (AT), liver, kidney, duodenum, jejunum, diaphragm, heart, subcutaneous AT, and brain were excised, immediately frozen in liquid nitrogen, and stored at -70°C until future tissue analysis.

Plasma and muscle sample analysis

Immunoreactive insulin and glucagon were assayed using a Linco Rat Radioimmunoassay kit (Linco Research, Inc., St. Charles, MO) and a double antibody method. Plasma epinephrine and norepinephrine levels were assessed by HPLC/EC after alumina extraction, elution, and pre-concentration. Cytokines were analyzed using multiplexing Luminex xMAP

technology (Luminex, Austin, TX). Plasma samples were prepared using mouse cytokine/chemokine Lincoplex kit (Linco research, St. Charles, MO). The plasma samples were deproteinized and both [2-¹⁴C]DG and [2-¹⁴C]DG-G-phosphate ([2-¹⁴C]DGP) radioactivity levels of the excised tissues was determined using liquid scintillation counting (Beckman LS 3801; Beckman Instruments, Inc, Irvin, CA).

Calculations

Glucose flux rates were assessed using non-steady state equations (29) assuming a volume of distribution (130 ml/kg). Tissue-specific clearance (K_g) of [2-¹⁴C]DG and glucose uptake (R_g) were calculated as previously described (17):

$$K_g = [2 - ^{14}\text{C}]DGP_{\text{tissue}} / \text{AUC} [2 - ^{14}\text{C}]DG_{\text{plasma}}$$

$$R_g = (K_g) ([\text{glucose}]_{\text{plasma}})$$

where [2-¹⁴C]DGP_{tissue} is the [2-¹⁴C]DGP radioactivity (dpm/g) in the tissue, AUC [2-¹⁴C]DG_{plasma} is the area under the plasma [2-¹⁴C]DG disappearance curve (dpm/mL/min), and [glucose]_{plasma} is the average blood glucose (μg/μl) during the experimental period. All data are presented as mean ± SEM and the significance level was set at $p < 0.05$.

Results

Cytokine Concentration

Blood IL-6 levels rose rapidly in WT following LPS injection. As expected, IL-6 was undetectable in KO mice. The IL-6 profile in the KO + IL-6 mice was successfully matched to the WT mice (Figure 1).

TNF- α levels were low in the basal period for all three groups. Following LPS injection TNF- α levels increased to ~1000 pg/mL by 30mins in WT mice and remained elevated for the remainder of the study. The rate of rise of TNF α was slower in KO and KO + IL-6 mice not reaching comparable levels until 180 min. Interestingly in KO mice TNF- α levels rapidly declined after 180 min (Figure 1). IL-10 increased to equivalent levels in all three groups by 180 mins after LPS injection although IL-10 rose earlier in KO. IL-1 β increased in all groups to a similar extent (Figure 2). Saline injection did not alter any of the cytokines in WT (data not presented).

Glucose Metabolism

Arterial blood glucose concentrations were similar during the basal period for KO and KO + IL-6, while WT mice had a significantly lower basal arterial glucose concentration (Figure 3). Within the first 60 mins following LPS injection, the arterial glucose concentration peaked for all three groups. Subsequently, glucose levels began to decrease, falling below baseline for all groups by 240 minutes, with the WT mice reaching glucose concentrations deemed hypoglycemic (70±8 mg/dl). Associated with this gradual fall in glucose was a progressive rise in glucose clearance above the basal rate in all three groups. The rate of glucose production (R_a) and glucose disappearance (R_d) remained similar between the three groups throughout the study (Figure 4). In all three groups the administration of LPS inhibited tissue glucose uptake (R_g) in the diaphragm, heart, and intrascapular adipose tissue but not in other tissues studied compared to control animals. Replacement of IL-6 in the KO mice lead to decreased R_g in the liver (Figures 5). These results were recapitulated in the tissue-specific glucose clearance (K_g ; data not shown).

Hormone Concentrations (Table 1)

During the basal time period, insulin levels were the same in the WT and KO + IL-6 replacement groups. However, insulin levels in the KO mice were significantly higher. Following LPS, insulin levels gradually decreased in all groups for the remainder of the study.

Glucagon and epinephrine levels increased in WT following LPS while they failed to increase in KO. Infusion of IL-6 in KO partially restored the glucagon but not the epinephrine response to LPS injection.

Discussion

Using our chronically catheterized conscious mouse model we assessed the endocrine, metabolic and cytokine response to LPS and the impact of the interleukin-6 deficiency. As shown in multiple species, LPS administrations lead to a transient increase in glucose concentration (23). In our wild type mice this increase in the arterial glucose concentration was followed by a gradual fall to induce mild hypoglycemia. In IL-6^{-/-} (KO) mice basal glucose concentration was increased which limited the extent of LPS induced hypoglycemia. Interestingly this increase occurred despite an absent epinephrine and glucagon response to LPS in KO. The acute replacement of IL-6 to restore the IL-6 response to endotoxin in KO mice did not alter the metabolic response to LPS. The transient rise in glucose concentration was primarily due to a rise in glucose appearance likely reflecting a rise in hepatic glucose production. LPS did not increase and in fact decreased glucose uptake in a number of tissues, which was not altered by the absence of IL-6. Despite attenuating the neuroendocrine response to LPS, the absence of IL-6 does not markedly alter the metabolic response.

As glucose production waned over time whole body glucose clearance gradually rose which explained the gradual development of mild hypoglycemia. In humans endotoxemia results in a hypermetabolic response characterized by an increase in glucose synthesis and release from the liver, leading to a brief state of hyperglycemia coupled with an elevated insulin concentration (1,18). This has been shown to lead to a state of insulin resistance (22). In rats Lang *et al* (20) demonstrated that the changes in glucose kinetics are dependent on the dose of LPS. The extent of the early rise in glucose increased as the dose of LPS was increased. However the severity of the hypoglycemia also was exacerbated at high doses of LPS. In dogs the hyperglycemic phase is less robust and hypoglycemia develops more readily (21). Our studies reveal a slightly different mechanism in the mouse. While all groups experienced an early transient hyperglycemia, we did not see an early elevation in insulin as has been reported in rats. The explanation for the differing kinetics in mice is unclear. The studies were done in a glycogen replete state and the likely mechanism for the rise in glucose production is a rise in hepatic glycogenolysis (21) Not surprisingly both epinephrine and glucagon increased which likely contributed to the initial rise in glucose flux (12).

The basal glucose concentration and the glucose excursion following LPS injection were exaggerated in IL-6 KO. This observation was interesting as studies conducted by Di Gregorio *et al* (8) have concluded that both WT and KO mice after a 4 hour fast had similar glucose levels, which ranged just below 200 mg/dL. The absence of IL-6 resulted in a more robust early hyperglycemic response to LPS and the absence of subsequent hypoglycemia. One might expect that the absence of IL-6 would improve insulin action as acute infusion of IL-6 impairs insulin action (15,26). While basal glucose concentrations were elevated in KO, the insulin concentration was not increased or only modestly increased suggesting only mild insulin resistance. However given the higher glucose concentration it is possible insulin

resistance combined with altered pancreatic endocrine function may contribute to the differing glucose concentration.

The absence of IL-6 delayed the TNF- α and hastened the IL-10 response to LPS. While the KO mice have no IL-6 paracrine or endocrine activity, the WT mice experienced an increase in both the paracrine and endocrine activity during exposure to LPS, which is in part, mediated through the upregulation of TNF- α observed during the early infection phase. As expected, our WT mice had a significant increase ($p < 0.03$) in TNF- α within the first 30 minutes following the LPS bolus, which was accompanied by a characteristic rise in IL-6. Fattori, *et al* (10) reported that in the absence of IL-6 there was a three-fold increase in TNF- α in these animals. Although our KO mice experienced an increase in TNF- α as well, this increase was delayed as compared to the WT mice. Since IL-6 can amplify TNF- α transcription, the absence of IL-6 in the KO mice may explain the observed delay in the TNF- α response (14).

The anti-inflammatory cytokine IL-10 has been associated with the counterregulatory effects of both IL-6 and TNF- α (11) and works primarily to quell the possible detrimental effects of these cytokines. Our finding draw a parallel with previous studies in that during early endotoxemia, IL-10 activation has a sluggish response during the time when TNF- α and subsequently IL-6 were first activated in WT mice. There is speculation that the early increase in the pro-inflammatory cytokines may actually suppress the beneficial early activation of IL-10 (11). Interestingly, our KO mice experienced an early activation of IL-10 and a delayed activation of TNF- α , which we believe is facilitated by the absence of the rise of IL-6 as IL-6 replacement delayed the IL-10 response. The beneficial effects of IL-10 may be masked by the increased levels of IL-6 observed during endotoxemia. These finding correlate with previous studies conducted where anti-TNF- α antibodies were given prior to a bolus of LPS; IL-6 and IL-1 β were blunted, whereas IL-10 had an increased early response (4).

We infused rmIL-6 into KO mice in an attempt to restore the endocrine effects observed in WT mice to LPS. Although we successfully recreated the IL-6 profile observed in the WT mice, the infusion of IL-6 did not correct the delayed TNF- α or IL-1 β response to LPS, but it did delay the IL-10 response. This could be explained by the need of the endocrine levels of IL-6 to reach a certain level to trigger the positive feedback response previously mentioned. This is especially relevant as the TNF- α levels in the KO+IL-6 group closely mirror the levels observed in WT mice from 180 minutes until the end of the study. These mice also displayed the same sluggish IL-10 response suggesting that the endocrine effects of IL-6 are an important modulator of the IL-10 response.

As previously mentioned KO and KO + IL-6 had similar fasting basal glucose concentrations and experienced an early transient hyperglycemia. We postulated that the infusion of IL-6 into the KO animals would recapitulate the immunological and hormonal responses observed in WT animals. These mice displayed a glucose profile similar to KO throughout the entirety of the study, even though there was a delayed response in both TNF- α and IL-10. This is interesting as it suggests the endocrine actions of IL-6 are not enough to alter glucose metabolism. It is also interesting to note that both KO and KO + IL-6 had a profound decrease in glucose clearance in the first 30 minutes while KO + IL-6 had a profound increase in clearance from 180 minutes until the end of the study ($P < 0.050$). The early decrease in clearance amplified the early rise in glucose in response to LPS in both groups.

The absence of IL-6 modulates the glucagon and epinephrine response to LPS. KO mice experienced decreased basal glucagon concentrations and a blunted increase in glucagon and

epinephrine in response to LPS. Interestingly simulation of the IL-6 response to LPS partially restored the glucagon but not the epinephrine response to LPS suggesting IL-6 stimulation regulates glucagon secretion. This observation is consistent with recent work suggesting IL-6 modulates alpha cell hyperplasia in response to high fat feeding (9). Despite IL-6 replacement partially restoring the glucagon response to LPS injection, glucose flux was not altered. This suggests that glucagon may play a minor role in sustaining glucose production following LPS.

In conclusion, the absence of IL-6 appeared to be protective against endotoxin induced hypoglycemia. It is possible that early alterations, glycemia variables, and cytokines allowed for the late term protective effects against hypoglycemia. Our data suggest end stage glucose levels observed in KO mice may be attributed to factors other than hormonal catabolic mediators such as glucagon, epinephrine, and norepinephrine as the epinephrine and glucagon response was markedly attenuated in the KO mice. This observation, coupled with the previously stated glucose kinetic profile, leads us to believe that carbohydrate metabolism is not altered directly through the properties of the IL-6 protein. Our studies indicate IL-6 is partly, but not entirely, responsible for the metabolic and immunologic profile seen during high dose endotoxemia. Likewise, the WT metabolic and immunologic response could not be recreated in the IL-6 replacement group, which leads us to believe that the changes observed during endotoxemia occur indirectly through either an IL-6 mediated transcription pathway or through a redundant immunological signaling pathway that includes IL-6.

Acknowledgments

This work was supported by National Institutes of Health Grants U24 DK-59637 and R01 DK-43748 and P30 DK-058404. Special thanks to the members of the Mouse Metabolic Phenotyping Center (Carlo Malabanan and Deanna Bracy) who implanted the catheters. Kimberly Mulligan was supported by the Molecular Endocrinology Training Grant T32-DK-07563.

References

1. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. *J Clin Endocrinol Metab* 2000;85:3770–3778. [PubMed: 11061537]
2. Ayala JE, Bracy D, McGuinness OP, Wasserman DH. Considerations in the Design of Hyperinsulinemic-Euglycemic Clamps in the Conscious Mouse. *Diabetes* 2006;55:390–397. [PubMed: 16443772]
3. Bagby GJ, Lang CH, Skrepnik N, Golightly G, Spitzer JJ. Regulation of glucose metabolism after endotoxin and during infection is largely independent of endogenous tumor necrosis factor. *CircShock* 1993;39:211–219.
4. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. *Science* 1985;229:869–871. [PubMed: 3895437]
5. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. *Diabetes* 2006;55:2688–2697. [PubMed: 17003332]
6. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans. *Clin Diagn Lab Immunol* 2005;12:60–67. [PubMed: 15642986]
7. Del Rey A, Besedovsky HO. Metabolic and neuroendocrine effects of pro-inflammatory cytokines. *Eur J Clin Invest* 1992;22 (Suppl 1):10–15. [PubMed: 1333964]
8. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. *Am J Physiol Endocrinol Metab* 2004;287:E182–187. [PubMed: 15191885]

9. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY. Interleukin-6 regulates pancreatic alpha-cell mass expansion. *Proc Natl Acad Sci U S A* 2008;105:13163–13168. [PubMed: 18719127]
10. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin 6-deficient mice. *J Exp Med* 1994;180:1243–1250. [PubMed: 7931061]
11. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. *J Exp Med* 1993;177:547–550. [PubMed: 8426124]
12. Hargrove DM, Bagby GJ, Lang CH, Spitzer JJ. Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. *AmJPhysiol* 1988;255:E629–E635.
13. Harizi H, Homo-Delarche F, Amrani A, Coulaud J, Mormède P. Marked genetic differences in the regulation of blood glucose under immune and restraint stress in mice reveals a wide range of corticosenitivity. *Journal of Neuroimmunology* 2007;189:59–68. [PubMed: 17658621]
14. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. *Surg Gynecol Obstet* 1988;166:147–153. [PubMed: 3122336]
15. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. *Diabetes* 2004;53:1060–1067. [PubMed: 15047622]
16. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic Exposure to Interleukin-6 Causes Hepatic Insulin Resistance in Mice. *Diabetes* 2003;52:2784–2789. [PubMed: 14578297]
17. Kraegen EW, James DE, Jenkins AB, Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. *AmJPhysiol* 1985;248:E353–362.
18. Krogh-Madsen R, Moller K, Dela F, Kronborg G, Jauffred S, Pedersen BK. Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. *Am J Physiol* 2004;286:E766–772.
19. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. *Am J Physiol Endocrinol Metab* 2006;291:E108–114. [PubMed: 16464907]
20. Lang CH, Bagby GJ, Spitzer JJ. Glucose kinetics and body temperature after lethal and nonlethal doses of endotoxin. *AmJPhysiol* 1985;248:R471–478.
21. Meinz HM, Lacy DB, Ejiofor J, McGuinness OP. Alterations in hepatic gluconeogenic amino acid uptake and gluconeogenesis in the endotoxin treated conscious dog. *Shock* 1998;9:296–303. [PubMed: 9565259]
22. Meszaros K, Bagby GJ, Lang CH, Spitzer JJ. Increased uptake and phosphorylation of 2-deoxyglucose by skeletal muscles in endotoxin-treated rats. *AmJPhysiol* 1987;253:E33–39.
23. Meszaros K, Bojta J, Bautista AP, Lang CH, Spitzer JJ. Glucose utilization by Kupffer cells, endothelial cells, and granulocytes in endotoxemic rat liver. *AmJPhysiol* 1991;260(Pt 1):G7–12.
24. Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. *JBiolChem* 1987;262:10965–10970.
25. Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Tumor necrosis factor increases in vivo glucose utilization of macrophage-rich tissues. *Biochemical & Biophysical Research Communications* 1987;149:1–6. [PubMed: 3689407]
26. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M. Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle. *Diabetes* 2008;57:3211–3221. [PubMed: 18796617]
27. Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. *JBiolChem* 1997;272:22570–22575.
28. Pedersen BK, Febbraio MA, Mooney RA. Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. *J Appl Physiol*. 2006

29. Wall JS, Steele R, De Bodo RC, Altszuler N. Effect of insulin on utilization and production of circulating glucose. *AmJPhysiol* 1957;189:43–50.
30. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED. Direct Cross-talk of Interleukin-6 and Insulin Signal Transduction via Insulin Receptor Substrate-1 in Skeletal Muscle Cells. *J Biol Chem* 2006;281:7060–7067. [PubMed: 16418171]
31. Wheeler AP, Bernard GR. Treating patients with severe sepsis. *N Engl J Med* 1999;340:207–214. [PubMed: 9895401]

Figure 1.

The plasma concentration of Interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) in pg/mL in WT, KO, and KO + IL-6. Data are expressed as mean ± SEM. * p<0.05 WT vs. KO

Figure 2.

The plasma concentration of Interleukin-1 β (IL-1 β) and Interleukin-10 (IL-10) in LPS injected wild type (WT) and interleukin-6 knockout (KO) mice, and KO receiving LPS and a simulated IL-6 infusion. Data are expressed as mean $\pm$ SEM.

Figure 3. Arterial Blood glucose concentration in LPS injected wild type, interleukin-6 knockout (KO) mice, and KO receiving LPS and a simulated IL-6 infusion. Data are expressed as mean $\pm$ SEM. * indicates $p < 0.05$ vs. WT

Figure 4. The rates of whole body glucose appearance (Ra) and disappearance (Rd) in LPS injected wild type, interleukin-6 knockout (KO) mice, and KO receiving LPS and a simulated IL-6 infusion. Data are expressed as mean $\pm$ SEM.

Figure 5.

The rates of tissue (soleus, gastrocnemius, white vastus lateralis, liver, gonadal adipose tissue, diaphragm, heart, brain, intrascapular adipose tissue, duodenum, jejunum and kidney) glucose uptake (R_g) in saline treated wild type (Control) animals and LPS injected wild type, interleukin-6 knockout (KO) mice, and KO receiving LPS and a simulated IL-6 infusion. Data are expressed as mean $\pm$ SEM. * $p < 0.05$ vs. Control

Table 1

Plasma insulin, glucagon and catecholamine response to LPS in chronically catheterized conscious wild type (WT), interleukin-6 knockout (KO), and KO mice receiving a simulated interleukin-6 infusion (KO+IL-6). Data are expressed as Mean $\pm$ SEM.

Time (min)	0	30	265
Insulin (ng/ml)			
WT	0.5 $\pm$ 0.1	0.4 $\pm$ 0.1	0.2 $\pm$ 0.1
KO	0.7 $\pm$ 0.1 [*]	0.7 $\pm$ 0.1	0.4 $\pm$ 0.1
KO+IL-6	0.5 $\pm$ 0.1	0.5 $\pm$ 0.3	0.3 $\pm$ 0.1
Glucagon (pg/ml)			
WT	157 $\pm$ 31	212 $\pm$ 56 [*]	243 $\pm$ 60
KO	53 $\pm$ 10	98 $\pm$ 11	97 $\pm$ 13
KO+IL-6	71 $\pm$ 18	127 $\pm$ 30	285 $\pm$ 40
Epinephrine (pg/ml)			
WT	70 $\pm$ 26	243 $\pm$ 75	522 $\pm$ 145 [*]
KO	22 $\pm$ 2	137 $\pm$ 39	109 $\pm$ 40
KO+IL-6	41 $\pm$ 10	89 $\pm$ 27	63 $\pm$ 18
Norepinephrine (pg/ml)			
WT	124 $\pm$ 27	244 $\pm$ 22	372 $\pm$ 60
KO	137 $\pm$ 19	224 $\pm$ 57	206 $\pm$ 42
KO+IL-6	226 $\pm$ 25	153 $\pm$ 15	208 $\pm$ 24

*
p<0.05